The stock is in a powerful, sustained uptrend, having appreciated 136.92% over the past year. With a current price of $104.91, it is trading at the very top of its 52-week range, just 0.07% below its 52-week high of $104.98, indicating strong momentum but also potential overextension. The stock has consolidated near these highs for several months, suggesting a period of digestion following the explosive move from below $70 in late October 2025 to above $100 by late November. Recent short-term momentum shows a deceleration from the explosive mid-to-late November surge, with a more modest 1.50% gain over the past month and a 3.03% gain over the past three months. This consolidation phase, characterized by low volatility and sideways trading in a tight range between approximately $101 and $104 since late November 2025, represents a healthy pause that has allowed the stock to work off overbought conditions following its 96.76% six-month surge. Key technical support is anchored at the 52-week low of $38.81, but more relevant near-term support lies in the $100-$101 consolidation zone that has held since late 2025. Immediate resistance is the 52-week high at $104.98; a decisive breakout above this level could signal a resumption of the primary uptrend. The stock exhibits high volatility relative to the market, with a beta of 1.442, meaning it is approximately 44% more volatile than the SPY, which is a critical consideration for risk management given its elevated price level.

Exact Sciences is demonstrating a robust revenue growth trajectory, with Q4 2025 revenue of $878.38 million representing a 23.12% year-over-year increase. Growth has been consistent and accelerating from prior quarters, with Q3 2025 revenue at $850.74 million (up 20.0% YoY) and Q2 2025 at $811.09 million (up 16.0% YoY). The Screening segment, which includes Cologuard, is the primary growth driver, generating $1.235 billion annually compared to $350 million from Precision Oncology, indicating the core screening business is scaling effectively. The company is on a clear path toward profitability, with net losses narrowing dramatically. The Q4 2025 net loss was $85.96 million (EPS of -$0.45), a significant improvement from the $864.59 million loss (EPS of -$4.67) in Q4 2024. Gross margins remain healthy and stable at 70.11% in Q4 2025, consistent with the 69.69% trailing twelve-month gross margin, indicating strong pricing power and cost control in its test portfolio. Balance sheet and cash flow health have improved substantially. The company generated $356.78 million in trailing twelve-month free cash flow, a stark turnaround from prior periods of cash burn. It maintains a solid liquidity position with a current ratio of 2.43 and holds $956 million in cash (as of Q4 2025). However, financial leverage remains a consideration with a debt-to-equity ratio of 1.05, though the strong positive free cash flow provides capacity to service this debt internally.